The PI3K-AKT signalling cascade has a highly conserved role in a variety of processes including cell growth and glucose homoeostasis. Variants affecting this pathway can lead to one of several segmental overgrowth disorders. These conditions are genetically heterogeneous and require tailored, multidisciplinary involvement throughout life. Hypoglycaemia is common in other overgrowth syndromes but has been described only sporadically in association with PIK3CA and CCND2 variants. We report a cohort of 6 children with megalencephaly-capillary malformation (MCAP) and megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndromes who developed clinically significant hypoglycaemia. Based on our findings, we suggest that segmental overgrowth patients should be screened for low blood glucose levels during childhood and there should be early specialist endocrine review in any children who develop hypoglycaemia. MCAP is caused by post-zygotic variants in PIK3CA (OMIM 171834) which can occur throughout the gene.
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| INTRODUCTION
The PI3K-AKT pathway is a highly conserved signalling cascade recognised as an important regulator of cell survival and growth. 1 Via receptor tyrosine kinase (RTK), insulin can activate PI3K-AKT signalling which controls glucose homoeostasis through various downstream molecules ( Figure 1 MCAP is caused by post-zygotic variants in PIK3CA (OMIM 171834) which can occur throughout the gene.
Children with a suspected diagnosis of MPPH or MCAP should undergo a thorough assessment as these disorders encompass multisystemic features, not specifically associated with overgrowth. 3 As such, the severity and heterogeneity of the segmental overgrowth spectrum requires a multidisciplinary approach. Here, we describe our experience of 6 individuals with MPPH or MCAP who developed clinically significant hypoglycaemia.
| METHODS
Patients were diagnosed with either MCAP or MPPH by a consultant clinical geneticist and reviewed by a paediatric endocrinologist.
Where insulin levels were measured at our centre, the lower limit of detection was 3 pmol/L. Hyperinsulinemic hypoglycaemia was diagnosed when the individual was hypoglycaemic (<3.0 mmol/L) with raised insulin levels or where high rate glucose infusions were required to achieve normoglycaemia. A definition of ketotic hypoglycaemia (KH) was applied where hypoglycaemia was accompanied by ketosis without raised insulin levels.
Patients' P1-P6 peripheral blood and skin or mouthwash samples were analysed as follows: long-range PCR and next generation sequencing on the Illumina MiSeq was used to analyse the entire coding region and flanking sequences to +/− 50 bp of PIK3CA (LRG_310t1) and PTEN (LRG_311t1) and targeted exons for PIK3R2
(NM_001759.3) and mTOR (LRG_734t1) with 100% coverage and a minimum exonic mean of ×1000 read depth. Regions with <×1000 read depth were retested via Sanger sequencing using BigDye v3.1.
Mutation/variant calling was via an in-house bioinformatics pipeline validated to detect mutations with a minimum of 5% mutant allele fraction. Mutation/variant naming was per HGVS guidelines (http:// www.hgvs.org/) using the reference sequences mentioned above.
All appropriate steps were taken to ensure no identifiable patient details were included in this report and that informed consent was sought. This work was reviewed and approved by our local ethics' review committee according to the principles outlined in the Helsinki Declaration.
| RESULTS
The heterogeneous clinical presentation of this cohort is outlined in Table 1 . Molecular analysis revealed somatic PIK3CA variants at varying levels of mosaicism in 4 of the 5 individuals whom had been diagnosed clinically as MCAP (P1-P4). A heterozygous CCND2 variant was identified from fibroblasts in P5 who was diagnosed with MPPH.
No variant was identified in P6, who was clinically diagnosed with MCAP.
Most patients developed hypoglycaemia soon after birth (Table 2 ). Admission to a Neonatal Intensive Care Unit (NICU) was necessary for patient P1 whose glucose requirement was calculated at >10 mg/kg/min. During this episode, the patient mounted a poor One of the most frequently observed side effects of mTOR inhibitors (mTORi) is hyperglycaemia which occurs in up to 50% of patients. 7 Early clinical trials of PI3K and AKT inhibitors have similarly shown hyperglycaemia as a major side effect, demonstrating the important role that the PI3K-AKT pathway plays in glucose homeostasis.
Via RTK, insulin activates the PI3K-AKT pathway which can engage mTOR to promote further insulin production and secretion, by encouraging beta cell growth. 8 Protracted activation of this pathway, specifically mediated via the mTOR Complex 1, causes hyperinsulinemic hypoglycaemia during early life in animal models. 9 In the neonatal period, our patients P1, P3 and P5 developed a similar pattern of hypoglycaemia. A comparable endocrine picture is also seen in Beckwith-Wiedemann (OMIM 130650) and Perlman (OMIM 267000) syndromes. Both disorders are associated with pancreatic islet cell hyperplasia and caused by pathogenic mechanisms considered distinct from the PI3K-AKT cascade. 10, 11 Interestingly, mTORi have been showed as effective in treating BWS patients with resistant hypoglycaemia, suggesting that the cascade has at least some modifying effect on the underlying endocrine pathology. 11 These Excessive sweating
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*Patient age at time of publication conditions have previously been described as "hyperinsulinism mimickers," presenting with clinical and biochemical sequel similar to congenital hyperinsulinism, without raised plasma insulin. 12 Sustained signalling of the PI3K-AKT cascade secondary to activating variants of PIK3CA may well have the potential to produce a similar endocrine phenotype. Ubiquitous expression of the PIK3CA H1047R variant in mouse models causes profound hypoinsulinemic hypoglycaemia, only partially rescued by AKT2 knockout, suggesting that PIK3CA controls glucose homeostasis via several downstream mechanisms. 13 Leiter et al 14 
